<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797714</url>
  </required_header>
  <id_info>
    <org_study_id>Promote</org_study_id>
    <nct_id>NCT05797714</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.</brief_title>
  <acronym>Promote</acronym>
  <official_title>A Prospective, Randomized, Blank Control, Multicenter Study to Evaluate the Efficacy and Safety of Alanine Aminotransferase（TMF）in the Treatment of Chronic Hepatitis B Patients With Normal Alanine Aminotransferase.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open, blank controlled trial ，in order to evaluate the&#xD;
      effectiveness and safety of Amibufenamide（TMF） in the treatment of chronic hepatitis B virus&#xD;
      infection patients with normal ALT at week 48.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the indications for antiviral therapy for patients with chronic hepatitis B have&#xD;
      been gradually expanded in different guidelines, antiviral treatment efficacy remains unclear&#xD;
      among patients with alanine aminotransferase (ALT) &lt; 1 upper limits of normal (ULN). This&#xD;
      study aimed to evaluate the the effectiveness and safety of TMF for these patients.&#xD;
&#xD;
      Tenofovir amibufenamide (TMF; codename: HS-10234), another formulation of tenofovir, shared&#xD;
      the same ProTide technology as tenofovir alafenamide, which can provide more efficient&#xD;
      intracellular delivery than TDF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2022</start_date>
  <completion_date type="Anticipated">April 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The subjects were randomly divided into two groups. One group received TMF treatment for 48 weeks. Aonther group received no antiviral therapy and served as a blank control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation the percentage of Participants with Hepatitis B Virus (HBV) DNA &lt; 20 IU/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>The primary efficacy endpoint was the proportion of patients with HBV DNA &lt; 20 IU/mL at week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation the change from Baseline in HBV DNA</measure>
    <time_frame>Week 48</time_frame>
    <description>Change from baseline in HBV DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the proportion of Patients Achieving Hepatitis B Surface Antigen (HBsAg) Loss</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of patients achieving Hepatitis B surface antigen (HBsAg) loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the proportion of Patients Achieving HBsAg Seroconversion</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of patients achieving HBsAg seroconversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the proportion of Patients Achieving HBeAg Seroconversion</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of patients achieving HBeAg seroconversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the proportion of Patients Achieving HBeAg Loss</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of patients Achieving HBeAg Loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the change from Baseline in HBsAg</measure>
    <time_frame>Week 48</time_frame>
    <description>Change from baseline in HBsAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the percentage of Participants with resistance</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the change from Baseline in liver fibrosis</measure>
    <time_frame>Week 48</time_frame>
    <description>Change from baseline in liver fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the proportion of Patients with get hepatitis acute attack（ALT &gt;5 ULN (40 IU/L)）</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of patients with get hepatitis acute attack（ALT &gt;5 ULN (40 IU/L)）</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HBV Infection</condition>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>TMF treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMF 25mg QD, from baseline to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blank control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No antiviral therapy is given. If ALT&gt;2 ULN (40 IU/L) for HBeAg-positive patients or &gt; ULN for HBeAg-negative patients during the study period, blank control group can be switched to TMF treatment once a day, 25mg/ time orally until the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Amibufenamide（TMF）</intervention_name>
    <description>TMF, 25mg QD, from baseline to 48 weeks</description>
    <arm_group_label>TMF treatment group</arm_group_label>
    <other_name>HengMu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have the ability to understand and sign a written informed consent form, which&#xD;
             must be obtained prior to initiation of study screening.&#xD;
&#xD;
          2. Male and non-pregnant, non-lactating females, from 18 up to 65 years of age (based on&#xD;
             the date of the screening visit). A negative serum pregnancy test at screening is&#xD;
             required for female subjects of childbearing potential.&#xD;
&#xD;
          3. Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6&#xD;
             months).&#xD;
&#xD;
          4. Normal alanine aminotransferase: serum HBV DNA &gt;20 IU/mL and serum ALT level ≤ULN (40&#xD;
             IU/L) during screening.&#xD;
&#xD;
          5. Treatment-naive subjects will be eligible for enrollment.&#xD;
&#xD;
          6. Must be willing and able to comply with all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women, women who are breastfeeding or who believe they may wish to become&#xD;
             pregnant during the course of the study.&#xD;
&#xD;
          2. Males and females of reproductive potential who are unwilling to use an &quot;effective&quot;,&#xD;
             protocol specified method(s) of contraception during the study.&#xD;
&#xD;
          3. Co-infection with HCV virus, HIV, HEV or HDV or combined with autoimmune liver&#xD;
             disease, metabolism-related fatty liver disease, drug-induced liver injury;&#xD;
&#xD;
          4. Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging).&#xD;
&#xD;
          5. Any history of, or current evidence of, clinical hepatic decompensation (e.g. ascites&#xD;
             encephalopathy or variceal hemorrhage) or liver stiffness over 9kpa measured by TE.&#xD;
&#xD;
          6. Abnormal hematological and biochemical parameters, including:&#xD;
&#xD;
             Hemoglobin &lt; 10 g/dl Absolute neutrophil count &lt; 0.75 × 10^9/L Platelets ≤ 50 × 10^9/L&#xD;
             AST &gt; 10 × ULN Total Bilirubin &gt; 2.5 × ULN Albumin &lt; 3.0 g/dL INR &gt; 1.5 × ULN (unless&#xD;
             stable on anticoagulant regimen) eGFR&lt;50mL/min&#xD;
&#xD;
          7. Received solid organ or bone marrow transplant.&#xD;
&#xD;
          8. Malignancy within the 5 years prior to screening, with the exception of specific&#xD;
             cancers that are cured by surgical resection (basal cell skin cancer, etc).&#xD;
&#xD;
          9. Currently receiving therapy with immunomodulators (e.g. corticosteroids),&#xD;
             investigational agents, nephrotoxic agents, or agents capable of modifying renal&#xD;
             excretion.&#xD;
&#xD;
         10. Complicated with uncontrollable cardiovascular and cerebrovascular diseases.&#xD;
&#xD;
         11. Subjects on prohibited concomitant medications. Subjects on prohibited medications,&#xD;
             otherwise eligible, will need a wash out period of at least 30 days,Known&#xD;
             hypersensitivity to study drugs, metabolites, or formulation excipients.&#xD;
&#xD;
         12. Current alcohol or substance abuse judged by the investigator to potentially interfere&#xD;
             with participant compliance.&#xD;
&#xD;
         13. Any other clinical condition or prior therapy that, in the opinion of the&#xD;
             Investigator, would make the subject unsuitable for the study or unable to comply with&#xD;
             dosing requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing You'An Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujun Zheng</last_name>
      <phone>15810716239</phone>
      <email>zhengsujun003@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Dongyang City</name>
      <address>
        <city>Dongyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YunZhen shi</last_name>
      <phone>13566947234</phone>
      <email>syzwylwmc@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuyang Second People's Hospital</name>
      <address>
        <city>Fuyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Tan</last_name>
      <phone>13861872462</phone>
      <email>TANL558@163.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang Province</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piao Hu</last_name>
      <phone>18969957010</phone>
      <email>hupiao2013@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LiShui People's Hospital of Zhejiang Province</name>
      <address>
        <city>LiShui</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JiaoJian LV</last_name>
      <phone>18957091505</phone>
      <email>lslvjiaojian@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Wu</last_name>
      <phone>133 3012 2823</phone>
      <email>Wuxiaoping2823@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Li</last_name>
      <phone>13905175333</phone>
      <email>dr-lijun@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Xie</last_name>
      <phone>13651804273</phone>
      <email>xieqinggrjh@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihong Qu</last_name>
      <phone>18916510601</phone>
      <email>18916510601@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Suzhou</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Qian</last_name>
      <phone>13913572662</phone>
      <email>fengqian70@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Wuxi</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanwang Qiu</last_name>
      <phone>13861872462</phone>
      <email>qywang839@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149. doi: 10.1111/apt.16611. Epub 2021 Sep 29.</citation>
    <PMID>34587302</PMID>
  </reference>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Normal Alanine Aminotransferase</keyword>
  <keyword>Treatment</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

